BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Ipca Laboratories Ltd. delivered an operationally inline Q1 FY23 performance. It remains on a robust growth path in the Domestic Formulation segment.
The successful process validation of certain products is expected to revive Ipca Labs' active pharma ingredient growth prospects over the medium term.
We cut our FY23/FY24 earnings per share estimate by 13%/7% to factor in:
increased operational cost on account of medical representatives addition and subsequent marketing expenses,
opex related to the Dewas facility,
opting of a higher tax rate going forward.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
POPULAR